The potential ameliorating effect of vitamin E on bleomycin − induced lung fibrosis in adult albino rats

• Published in: International immunopharmacology 2024-07, Vol.136, p.112375, Article 112375
• Main Authors: Mady, Basma, Ibrahim, Heba F., ElAziz MM, Abd, Basta, Marianne, Assem, Sara, Ahmed Ali, Manal, El Mottelib, Lobna M.M.A. Abd
• Format: Article
• Language: English
• Subjects: Actins - metabolism; Animals; Antioxidants; Antioxidants - pharmacology; Antioxidants - therapeutic use; Bleomycin; BLM; Cadherins - metabolism; Disease Models, Animal; Humans; Lung - drug effects; Lung - pathology; Lung fibrosis; Male; Malondialdehyde - metabolism; Oxidative stress; Pulmonary Fibrosis - chemically induced; Pulmonary Fibrosis - drug therapy; Pulmonary Fibrosis - pathology; Rats; Rats, Wistar; Smad3 Protein - metabolism; Superoxide Dismutase - metabolism; TGF-β; Transforming Growth Factor beta - metabolism; Vitamin E; Vitamin E - pharmacology; Vitamin E - therapeutic use
• ISSN: 1567-5769; 1878-1705; 1878-1705
• DOI: 10.1016/j.intimp.2024.112375

•Bleomycin offers a reliable model of lung fibrosis for experimental research.•Vitamin E inhibits TGF-β /α-SMA/collagen I profibrotic pathway in lung tissues.•Vitamin E is able to prevent lung fibrosis.•Vitamin E could be used as an adjuvant therapy for lung fibrosis. Lung fibrosis is a critical interstitial lung disease with poor prognosis. There is an urgent need to develop a proper and cost-effective therapeutic modality that can reverse and/or ameliorate lung fibrosis. Vitamin E is one of the widely investigated dietary antioxidants which has been linked to improvement of many health problems. The current study was conducted to evaluate the possible roles of vitamin E in prevention and treatment of bleomycin (BLM) induced lung fibrosis. Physiological, anatomical, histopathological and immunohistochemical studies were done to assess and compare between the structure and function of the lung tissue in lung fibrosis model, early and late treated groups with vitamin E. Furthermore, measurement of transforming growth factor-β(TGF-β), E-cadherin, Smad-3, BAX, BCL2, malondialdehyde (MDA), and superoxide dismutase (SOD) were done. The study revealed that administration of vitamin E helped to improve signs of lung fibrosis, as reflected by amelioration of structure and functions of lungs as well as the decrease in TGF-β levels and inhibition of α-SMA/collagen I profibrotic pathway. These findings highlight the importance of administration of vitamin E as a prophylactic agent prior to BLM therapy and as an adjuvant treatment in cases of lung fibrosis.